Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Gynaecology and Fertility

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%

Coronary events (MI or cardiac death) · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher coronary events (MI or cardiac death) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.89 [1.15, 3.1]
2 studies · 20993 participants
Moderate

Stroke · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 146 [1.02, 2.09]
2 studies · 17585 participants
Moderate

Venous thromboembolism · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 4.28 [2.49, 7.34]
2 studies · 20993 participants
Moderate

Breast cancer · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher breast cancer compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.27 [1.03, 1.56]
1 study · 16608 participants
Moderate

Mortality: lung cancer · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher death from lung cancer compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.74 [1.18, 2.55]
1 study · 16608 participants
Moderate

Gallbladder disease · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.64 [1.3, 2.06]
1 study · 14203 participants
Moderate

All clinical fractures · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 0.78 [0.71, 0.86]
1 study · 16608 participants
Moderate